User login
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss research highlights at Thursday's sessions of 2012 San Antonio Breast Cancer Symposium, including the CALOR trial, in which chemotherapy prolonged survival for isolated local or regional recurrence of breast cancer; use of neoadjuvant chemotherapy in patients 35 years of age or younger; and profiling triple-negative breast cancers.
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss research highlights at Thursday's sessions of 2012 San Antonio Breast Cancer Symposium, including the CALOR trial, in which chemotherapy prolonged survival for isolated local or regional recurrence of breast cancer; use of neoadjuvant chemotherapy in patients 35 years of age or younger; and profiling triple-negative breast cancers.
Dr. Howard A. "Skip" Burris III, editor-in-chief of The Oncology Report, and associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss research highlights at Thursday's sessions of 2012 San Antonio Breast Cancer Symposium, including the CALOR trial, in which chemotherapy prolonged survival for isolated local or regional recurrence of breast cancer; use of neoadjuvant chemotherapy in patients 35 years of age or younger; and profiling triple-negative breast cancers.